康华生物(300841) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥278,114,028.88, representing a 4.27% increase compared to ¥266,736,074.86 in the same period last year[4]. - Net profit attributable to shareholders decreased by 22.24% to ¥105,190,616.53 from ¥135,277,246.77 year-on-year[4]. - The basic earnings per share decreased by 21.94% to ¥0.7865 from ¥1.0076 in the same period last year[4]. - The total comprehensive income attributable to the parent company was CNY 105,190,616.53, a decrease of 22.2% compared to CNY 135,277,246.77 in the previous period[54]. - Net profit for the period was ¥11,698,408.06, a decrease from ¥20,857,091.39, reflecting a decline of approximately 43.5%[68]. - The company's total profit amounted to ¥116,889,024.59, down from ¥156,134,338.16, showing a decrease of around 25.1%[68]. - The profit attributable to the parent company's owners was ¥105,190,616.53, down from ¥135,277,246.77, a decline of approximately 22.2%[68]. Cash Flow - The net cash flow from operating activities improved significantly by 115.11%, reaching ¥16,892,087.59 compared to a negative cash flow of ¥111,805,582.88 in the previous year[4]. - The net cash flow from operating activities for Q1 2023 was ¥16,892,087.59, a significant improvement of 115.11% compared to the net cash flow of -¥111,805,582.88 in the same period last year[39]. - The company's cash flow from operating activities was positively impacted by an increase in sales scale and collection of receivables during the reporting period[39]. - Cash flow from operating activities rose significantly to ¥264,625,524.15 compared to ¥166,590,278.00, indicating an increase of about 58.8%[69]. Expenses and Costs - Research and development expenses increased by 131.58% to ¥48,657,680.12 from ¥21,011,414.14 in the same period last year, indicating a focus on innovation[21]. - Total operating costs increased to ¥166,597,332.57 from ¥120,171,079.04, representing a growth of approximately 38.5%[68]. - Sales expenses increased to ¥78,388,151.54 from ¥68,683,500.63, which is an increase of approximately 14.8%[68]. - Management expenses rose to ¥22,181,067.10, up from ¥19,138,952.77, reflecting an increase of about 15.9%[68]. - The company reported a financial expense of -¥1,722,386.08, improving from -¥5,294,864.03, indicating a reduction in financial costs[68]. Assets and Liabilities - The total assets at the end of Q1 2023 were ¥3,750,403,965.88, a 1.06% increase from ¥3,711,065,217.69 at the end of the previous year[4]. - The total liabilities amounted to CNY 568,940,998.03, down from CNY 635,397,264.58, representing a decrease of 10.5%[67]. - The company's equity attributable to shareholders rose by 3.44% to ¥3,181,462,967.85 from ¥3,075,667,953.11 year-on-year[4]. - The total equity attributable to the parent company increased to CNY 3,181,462,967.85 from CNY 3,075,667,953.11, showing a growth of 3.4%[67]. - The company reported a significant reduction in contract liabilities by 63.88%, down to ¥84,517.47 from ¥233,998.33[6]. - The company reported a decrease in employee compensation payable from CNY 28,300,512.77 to CNY 10,459,512.57, a reduction of 63.0%[67]. Other Information - The first quarter report was not audited, indicating that the figures presented are preliminary and subject to change[31]. - The company has not disclosed any new product or technology developments in the current report[59]. - There were no significant mergers or acquisitions reported during the period[59]. - The company has not indicated any major market expansion strategies in the current report[59]. - The company confirmed that there are no restatements or adjustments required for previous accounting data[58].